After-Hours Stock Movers 01/26: (NOW) (XM) (NFLX) Higher; (EPZM) (LC) (ZYME) Lower (more...)

January 26, 2022 5:58 PM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

After-Hours Stock Movers:

Epizyme, Inc. (Nasdaq: EPZM) 24.2% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the offering. All of the shares in the proposed offering are to be sold by Epizyme.

LendingClub (NYSE: LC) 10.8% LOWER; reported Q4 EPS of $0.27, $0.05 better than the analyst estimate of $0.22. Revenue for the quarter came in at $262.2 million versus the consensus estimate of $245.8 million. LendingClub sees Q1 2022 revenue of $255-265 million, versus the consensus of $257 million. LendingClub sees FY2022 revenue of $1.1-1.2 billion, versus the consensus of $1.16 billion.

ServiceNow (NYSE: NOW) 10.5% HIGHER; reported Q4 EPS of $1.46, $0.03 better than the analyst estimate of $1.43. Revenue for the quarter came in at $1.61 billion versus the consensus estimate of $1.6 billion. Sees Q1 Subscription revenues of $1.61-$1.615 billion. Sees FY22 Subscription revenues of $7.02-$7.04 billion.

Zymeworks Inc. (NYSE: ZYME) 9.6% LOWER; announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.

Qualtrics International (NASDAQ: XM) 9.3% HIGHER; reported Q4 EPS of ($0.07), $0.05 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $316 million versus the consensus estimate of $297.61 million.

Galapagos NV (NASDAQ: GLPG) 7.5% HIGHER; announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.

Flex Ltd. (NASDAQ: FLEX) 6% HIGHER; reported Q3 EPS of $0.50, $0.13 better than the analyst estimate of $0.37. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $5.6 billion. Flex Ltd. sees Q4 2022 EPS of $0.41-$0.46, versus the consensus of $0.39. Flex Ltd. sees Q4 2022 revenue of $6.2-6.6 billion, versus the consensus of $5.68 billion. Flex Ltd. sees FY2022 EPS of $1.85-$1.90, versus the consensus of $1.58. Flex Ltd. sees FY2022 revenue of $25.4-25.8 billion, versus the consensus of $22.34 billion.

Levi (NYSE: LEVI) 5.8% HIGHER; reported Q4 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.68 billion. Levi sees FY2022 EPS of $1.50-$1.56, versus the consensus of $1.53. Levi sees FY2022 revenue of $6.4-6.5 billion, versus the consensus of $6.38 billion.

Lam Research (NASDAQ: LRCX) 5.8% LOWER; reported Q4 EPS of $8.53, $0.02 better than the analyst estimate of $8.51. Revenue for the quarter came in at $4.23 billion versus the consensus estimate of $4.41 billion. Lam Research sees Q1 2023 EPS of $7.45 at the midpoint, versus the consensus of $8.72. Lam Research sees Q1 2023 revenue of $4.25 billion at the midpoint, versus the consensus of $4.49 billion.

Edwards Lifesciences (NYSE: EW) 5% LOWER; reported Q4 EPS of $0.51, $0.04 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $1.33 billion versus the consensus estimate of $1.36 billion. Edwards Lifesciences sees Q1 2022 EPS of $0.54-$0.62, versus the consensus of $0.60. Edwards Lifesciences sees Q1 2022 revenue of $1.27-1.35 billion, versus the consensus of $1.36 billion. Edwards Lifesciences sees FY2022 EPS of $2.50-$2.65, versus the consensus of $2.58. Edwards Lifesciences sees FY2022 revenue of $5.5-6 billion, versus the consensus of $5.82 billion.

Centene (NYSE: CNC) 5% HIGHER; fielded takeover interest from Cigna Corp. (NYSE: CI) in recent months, according to Bloomberg, citing people familiar with the matter.

Netflix (NASDAQ: NFLX) 4.5% HIGHER; Bill Ackman said his Pershing Square hedge fund bought over 3.1 million shares of Netflix following the recent slide in the stock. This makes the firm a top-20 holder.

Intel (NASDAQ: INTC) 2.6% LOWER; reported Q4 EPS of $1.09, $0.19 better than the analyst estimate of $0.90. Revenue for the quarter came in at $20.5 billion versus the consensus estimate of $18.32 billion. Intel sees Q1 2022 EPS of $0.80, versus the consensus of $0.86. Intel sees Q1 2022 revenue of $18.3 billion, versus the consensus of $17.62 billion.

Tesla (NASDAQ: TSLA) 1.2% HIGHER; reported Q4 EPS of $2.54, $0.28 better than the analyst estimate of $2.26. Revenue for the quarter came in at $17.72 billion versus the consensus estimate of $16.35 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

William Ackman, Pershing Square Capital, After-Hours Movers, Tesla